New Member Brings Strong Oncology Expertise
BOULDER, Colo.--(BUSINESS WIRE)--April 18, 2007--Array BioPharma
Inc. (NASDAQ: ARRY) today announced the appointment of Neil Spector,
M.D., to its Scientific Advisory Board. Dr. Spector will focus on
helping Array in the development of its cancer portfolio.
"Dr. Spector's experience, bringing two targeted anti-cancer
therapies from the bench all the way to market, will be a valuable
asset for Array," said Kevin Koch, Ph.D., President and Chief
Scientific Officer, Array BioPharma. "As the former Director of
GlaxoSmithKline's Exploratory Medical Sciences in Oncology and the
current Director of Translational Research in Oncology at Duke
University Medical Center, he will contribute valuable knowledge and
expertise as we move our oncology programs forward in clinical
development."
"It is a great opportunity to participate in developing Array's
promising drug pipeline," said Dr. Spector. "I look forward to helping
to guide the development of Array's breakthrough treatments for cancer
as a member of the Scientific Advisory Board."
Background - Neil Spector, M.D.
Dr. Spector, with 20 years of oncology experience, recently joined
Duke University Medical Center's cancer drug development team as the
new Director of Translational Research in Oncology. He also serves as
Co-Director of the Experimental Therapeutics Program in the cancer
center. Prior to joining Duke, Dr. Spector served as Director of
GlaxoSmithKline's Exploratory Medical Sciences in Oncology, where he
successfully developed two important cancer drugs, Tykerb (lapatinib)
and Nelarabine (ara-G analog), from the bench to the clinic and then
guided them through Food and Drug Administration (FDA) approval.
Dr. Spector received his medical degree from New Jersey Medical
School, UMDNJ. He completed his internship and residency at University
of Texas - Southwestern Parkland Memorial Hospital. His teaching
experience also includes seven years at the Dana-Farber Cancer
Institute in Boston and five years as an Assistant Professor of
Medicine at the University of Miami.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat life-threatening and debilitating diseases.
Our proprietary drug development pipeline is focused on the treatment
of cancer and inflammatory disease and includes clinical candidates
that are designed to regulate therapeutically important targets. In
addition, leading pharmaceutical and biotechnology companies
collaborate with Array to discover and develop drug candidates across
a broad range of therapeutic areas. For more information on Array,
please go to www.arraybiopharma.com.
Forward-Looking Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve significant risks and uncertainties, including those discussed
in our annual report filed on form 10-K for the year ended June 30,
2006, and in other reports filed by Array with the Securities and
Exchange Commission. Because these statements reflect our current
expectations concerning future events, our actual results could differ
materially from those anticipated in these forward-looking statements
as a result of many factors. These factors include, but are not
limited to, our ability to continue to fund and successfully progress
internal research efforts and to create effective, commercially viable
drugs, our ability to achieve and maintain profitability, the extent
to which the pharmaceutical and biotechnology industries are willing
to in-license drug candidates for their product pipelines and to
collaborate with and fund third parties on their drug discovery
activities, our ability to out-license our proprietary candidates on
favorable terms, risks associated with our dependence on our
collaborators for the clinical development and commercialization of
our out-licensed drug candidates, the ability of our collaborators and
of Array to meet objectives tied to milestones and royalties, and our
ability to attract and retain experienced scientists and management.
We are providing this information as of April 18, 2007. We undertake
no duty to update any forward-looking statements to reflect the
occurrence of events or circumstances after the date of such
statements or of anticipated or unanticipated events that alter any
assumptions underlying such statements.
CONTACT: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
SOURCE: Array BioPharma Inc.
